New diabetes drug semaglutide put to the test in argentine Real-World study
NCT ID NCT07621419
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is tracking 145 adults with type 2 diabetes in Argentina who are starting semaglutide (either as a pill or injection) as part of their normal care. Researchers will measure changes in blood sugar, weight, waist size, and grip strength over 12 months, along with how satisfied patients are with the treatment. The goal is to see how well semaglutide works in real-life settings, not just in tightly controlled clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
semaglutide (oral and injectable forms)
What this could lead to
If successful, this study could confirm that semaglutide works well in everyday Argentine clinics, helping doctors choose the best treatment for type 2 diabetes.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It is also relatively small (145 people) and only follows patients for one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital General de Agudos Dr Enrique Tornú
RECRUITINGBuenos Aires, Buenos Aires, 1427, Argentina
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Italiano de Buenos Aires
RECRUITINGBuenos Aires, Buenos Aires, 1199, Argentina
Contact Phone: •••-•••-•••• Email: •••••@•••••